Erratum: Measuring unbound versus total vancomycin concentrations in serum and plasma: Methodological issues and relevance (Therapeutic Drug Monitoring DOI: 10.1097/FTD.0000000000000122);Measuring unbound versus total vancomycin concentrations in serum and plasma: Methodological issues and relevance

Therapeutic Drug Monitoring

Volumn 37, Issue 2, 2015, Pages 180-187

  Stove, Veronique ^a   Coene, Louise ^a   Carlier, Mieke ^b   De Waele, Jan J ^a   Fiers, Tom ^a   Verstraete, Alain G ^a,b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

equilibrium dialysis; protein binding; ultrafiltration; unbound concentrations; vancomycin

Indexed keywords

ALBUMIN; BINDING PROTEIN; IMMUNOGLOBULIN A; OROSOMUCOID; VANCOMYCIN; ANTIINFECTIVE AGENT; PLASMA PROTEIN;

ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; EQUILIBRIUM DIALYSIS; HUMAN; MYELOMA; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONTENT; TOTAL DRUG CONCENTRATION; ULTRAFILTRATION; UNBOUND DRUG CONCENTRATION; BLOOD; METABOLISM; REPRODUCIBILITY; STATISTICAL MODEL; TEMPERATURE;

ANTI-BACTERIAL AGENTS; BLOOD PROTEINS; HUMANS; LINEAR MODELS; REPRODUCIBILITY OF RESULTS; TEMPERATURE; ULTRAFILTRATION; VANCOMYCIN;

EID: 84925946080     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000219     Document Type: Erratum

References (24)

1. Roberts JA, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet. 2013;52:1-8.
2. Musteata FM. Monitoring free drug concentrations: challenges. Bioanal-ysis. 2011;3:1753-1768.
3. Zeitlinger MA, Derendorf H, Mouton JW, et al. Protein binding: do we ever learn? Antimicrob Agents Chemother. 2011;55:3067-3074.
4. Nilsson LB. The bioanalytical challenge of determining unbound concentration and protein binding for drugs. Bioanalysis. 2013;5:3033-3050.
5. Kees MG, Wicha SG, Seefeld A, et al. Unbound fraction of vancomycin in intensive care unit patients. J Clin Pharmacol. 2014;54:318-323.
6. Berezhkovskiy LM. On the temperature dependence of the unbound drug fraction in plasma: ultrafiltration method may considerably underestimate the true value for highly bound drugs. Drug Discov Ther. 2008;2:74-76.
7. Sun H, Maderazo EG, Krusell AR. Serum protein-binding characteristics of vancomycin. Antimicrob Agents Chemother. 1993;37:1132-1136.
8. Morita K, Yamaji A. Changes in the serum protein binding of vancomy-cin in patients with methicillin-resistant Staphylococcus aureus infection: the role of serum alpha 1-acid glycoprotein levels. Ther Drug Monit. 1995;17:107-112.
9. Dykhuizen RS, Harvey G, Stephenson N, et al. Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob Agents Chemother. 1995;39:1842-1847.
10. Berthoin K, Ampe E, Tulkens PM, et al. Correlation between free and total vancomycin serum concentrations in patients treated for Grampositive infections. Int J Antimicrob Agents. 2009;34:555-560.
11. Butterfield JM, Patel N, Pai MP, et al. Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding. Antimicrob Agents Chemother. 2011;55:4277-4282.
12. Crandon JL, MacVane SH, Nicolau DP. Clinical laboratory-based assay methodologies may underestimate and increase variability of vancomy-cin protein binding in hospitalized patients. Pharmacotherapy. 2014;34: 203-209.
13. Ampe E, Delaere B, Hecq JD, et al. Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects. Int J Antimicrob Agents. 2013;41:439-446.
14. Ulldemolins M, Roberts JA, Rello J, et al. The effects of hypoalbumi-naemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50:99-110.
15. Wu J, Wei R, Wang H, et al. Underlying the mechanism of vancomycin and human serum albumin interaction: a biophysical study. J Biochem Mol Toxicol. 2013;27:463-470.
16. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29:1275-1279.
17. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and tox-icity. Arch Intern Med. 2006;166:2138-2144.
18. Grace E. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. J Antimicrob Chemother. 2012;67:1305-1310.
19. Rice TL. Simplified dosing and monitoring of vancomycin for the burn care clinician. Burns. 1992;18:355-361.
20. Cantu TG, Dick JD, Elliott DE, et al. Protein binding of vancomycin in a patient with immunoglobulin A myeloma. Antimicrob Agents Chemother. 1990;34:1459-1461.
21. Zokufa HZ, Solem LD, Rodvold KA, et al. The influence of serum albumin and alpha 1-acid glycoprotein on vancomycin protein binding in patients with burn injuries. J Burn Care Rehabil. 1989;10:425-428.
22. Yue B, Rockwood AL, Sandrock T, et al. Free thyroid hormones in serum by direct equilibrium dialysis and online solid-phase extraction- liquid chromatography/tandem mass spectrometry. Clin Chem. 2008;54: 642-651.
23. Schouwers S, Verstraete A, Stove V. Analytical evaluation of phenytoin, phenobarbital, valproic acid and vancomycin assays on the Abbott Architect™. Acta Clin Belg. 2010;65:211.
24. Roberts JA, Stove V, De Waele JJ, et al. Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI study. Int J Antimicrob Agents. 2014;43:423-430.